PMID- 15792683
OWN - NLM
STAT- MEDLINE
DCOM- 20050926
LR  - 20131121
IS  - 0049-3848 (Print)
IS  - 0049-3848 (Linking)
VI  - 115
IP  - 6
DP  - 2005
TI  - Effect of subcutaneous administration of dalteparin on lupus anticoagulant 
      assays.
PG  - 509-17
AB  - INTRODUCTION: Treatment with unfractionated heparin (UH) is known to affect 
      screening tests for lupus anticoagulant (LA). False positive test results are 
      common because confirmatory steps lack sufficient specificity to distinguish 
      between LA and the presence of heparin. In this study, we wanted to see if 
      therapeutic levels of low-molecular weight heparin (LMWH) may cause false 
      positive tests for LA or alter the LA test results in LA-positive patients. We 
      also wanted to evaluate the need to include heparin-neutralizing agents in the 
      reagents. MATERIALS AND METHODS: Six healthy subjects without LA and six 
      LA-positive patients were given 100 IU/kg dalteparin subcutaneously (s.c.). 
      Samples for three in-house and two commercially available LA tests were taken 
      before and 4 h after the injection. LA test results were calculated as normalized 
      screening/confirm ratios or as recommended by the manufacturers. RESULTS: With 
      both healthy subjects and LA patients, only small and clinically unimportant 
      differences in mean clotting times and final test results were seen 4 h after 
      subcutaneous dalteparin injections, at anti-FXa activities within the therapeutic 
      range. CONCLUSIONS: Our study with dalteparin suggests that LMWH therapy with 
      plasma concentrations within the therapeutic range does not cause false positive 
      tests for LA when normalized screening/confirm ratios are applied; nor do test 
      results for LA-positive patients seem to be significantly altered. 
      Heparin-neutralizing agents did not influence test performance.
FAU - Liestol, Sigurd
AU  - Liestol S
AD  - Haematological Research Laboratory, Medical Clinic, Ulleval University Hospital, 
      N-0407 Oslo, Norway. sigurdli@ioks.uio.no
FAU - Wisloff, Finn
AU  - Wisloff F
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20041218
PL  - United States
TA  - Thromb Res
JT  - Thrombosis research
JID - 0326377
RN  - 0 (Lupus Coagulation Inhibitor)
RN  - 9005-49-6 (Heparin)
RN  - S79O08V79F (Dalteparin)
SB  - IM
MH  - Adult
MH  - *Blood Coagulation Tests
MH  - Dalteparin/*administration & dosage
MH  - False Positive Reactions
MH  - Female
MH  - Heparin/chemistry/metabolism
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Lupus Coagulation Inhibitor/*analysis/blood
MH  - Male
MH  - Middle Aged
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
EDAT- 2005/03/29 09:00
MHDA- 2005/09/27 09:00
CRDT- 2005/03/29 09:00
PHST- 2004/08/30 00:00 [received]
PHST- 2004/11/15 00:00 [revised]
PHST- 2004/11/16 00:00 [accepted]
PHST- 2005/03/29 09:00 [pubmed]
PHST- 2005/09/27 09:00 [medline]
PHST- 2005/03/29 09:00 [entrez]
AID - S0049-3848(04)00595-X [pii]
AID - 10.1016/j.thromres.2004.11.013 [doi]
PST - ppublish
SO  - Thromb Res. 2005;115(6):509-17. doi: 10.1016/j.thromres.2004.11.013. Epub 2004 
      Dec 18.